P21

Overview

P21 — often written P021 — is a small synthetic peptide derived from a biologically active fragment of ciliary neurotrophic factor (CNTF). Researchers identified a short active region of the much larger CNTF protein and added an adamantane group, a compact cage-like molecule that increases lipophilicity and helps the peptide cross the blood-brain barrier while resisting enzymatic degradation.

It is studied as a nootropic and neurotrophic compound, meaning it is investigated for its potential to support the growth and maintenance of neurons and to influence learning and memory. The goal of its design was to capture the neurogenic benefits attributed to CNTF in a smaller, more stable molecule without the drawbacks of the full protein.

The evidence for P21 is entirely preclinical. It has been examined in mice and rats but, as of this writing, has not been evaluated in published human clinical trials. It is not approved for therapeutic use by any major regulator.

How it works

In animal studies, P21 is reported to promote neurogenesis — the formation of new neurons — in the dentate gyrus of the hippocampus, a region associated with learning and memory. This effect is thought to involve inhibition of leukemia inhibitory factor (LIF) signaling together with increased expression of brain-derived neurotrophic factor (BDNF).

Researchers have also linked P21 to reduced activity of glycogen synthase kinase-3β (GSK-3β), an enzyme involved in tau phosphorylation, which is why it has been explored in models of Alzheimer’s disease and cognitive aging. The precise mechanism, and whether any of it translates to humans, remains unestablished.

Reported benefits

• Enhanced neurogenesis in the hippocampus (rodent data)
• Improved performance on learning and memory tasks in animal models
• Reduced tau- and amyloid-related pathology in Alzheimer’s disease models (preclinical)
• Support for synaptic plasticity in aged animals

These are reported findings from animal research, not established outcomes in humans.

Considerations & side effects

Because P21 has not been studied in humans, its safety profile, tolerability, and long-term effects are unknown. There is no established human side-effect data, and any use outside of a research setting carries uncertain risk.

Purity and identity vary widely in the research-chemical market, and P21 is sold for laboratory research only. It is not a medicine and is not a substitute for evaluation and treatment by a qualified clinician.